LTGO
NASDAQ HealthcareLatigo Biotherapeutics, Inc. - Common Stock
Biotechnology
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain. Latigo Biotherapeutics, Inc. was formerly known as WVB-Desmond, Inc. and changed its name to Latigo Biotherapeutics, Inc. in March 2019. Latigo Biotherapeutics, Inc. was incorporated in 2018 and is based in Thousand Oaks, California.
�� 市场数据
| 价格 | $19.30 |
|---|---|
| 成交量 | 172,173 |
| 市值 | 1.16B |
| 52周最高 | $22.47 |
| 52周最低 | $17.22 |
| Price / Book | -0.45 |
🎯 投资策略评分
LTGO 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🔪 Falling Knife (64/100) — 此策略 逆向投资（超卖 + 低于移动均线）.
评分最低的策略： 🚀 Moon Shot (12/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
在文本中查找 LTGO in your text
粘贴任何文章、记录或帖子 — 工具将提取 LTGO 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-08-17.